GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Forma Therapeutics Holdings Inc (NAS:FMTX) » Definitions » Current Ratio

Forma Therapeutics Holdings (Forma Therapeutics Holdings) Current Ratio : 12.74 (As of Jun. 2022)


View and export this data going back to 2020. Start your Free Trial

What is Forma Therapeutics Holdings Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Forma Therapeutics Holdings's current ratio for the quarter that ended in Jun. 2022 was 12.74.

Forma Therapeutics Holdings has a current ratio of 12.74. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.

The historical rank and industry rank for Forma Therapeutics Holdings's Current Ratio or its related term are showing as below:

FMTX' s Current Ratio Range Over the Past 10 Years
Min: 1.09   Med: 15.13   Max: 20.65
Current: 12.74

During the past 4 years, Forma Therapeutics Holdings's highest Current Ratio was 20.65. The lowest was 1.09. And the median was 15.13.

FMTX's Current Ratio is not ranked
in the Biotechnology industry.
Industry Median: 3.71 vs FMTX: 12.74

Forma Therapeutics Holdings Current Ratio Historical Data

The historical data trend for Forma Therapeutics Holdings's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Forma Therapeutics Holdings Current Ratio Chart

Forma Therapeutics Holdings Annual Data
Trend Dec18 Dec19 Dec20 Dec21
Current Ratio
1.09 7.13 20.65 13.86

Forma Therapeutics Holdings Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.94 16.39 13.86 16.95 12.74

Competitive Comparison of Forma Therapeutics Holdings's Current Ratio

For the Biotechnology subindustry, Forma Therapeutics Holdings's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Forma Therapeutics Holdings's Current Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Forma Therapeutics Holdings's Current Ratio distribution charts can be found below:

* The bar in red indicates where Forma Therapeutics Holdings's Current Ratio falls into.



Forma Therapeutics Holdings Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

Forma Therapeutics Holdings's Current Ratio for the fiscal year that ended in Dec. 2021 is calculated as

Current Ratio (A: Dec. 2021 )=Total Current Assets (A: Dec. 2021 )/Total Current Liabilities (A: Dec. 2021 )
=486.401/35.088
=13.86

Forma Therapeutics Holdings's Current Ratio for the quarter that ended in Jun. 2022 is calculated as

Current Ratio (Q: Jun. 2022 )=Total Current Assets (Q: Jun. 2022 )/Total Current Liabilities (Q: Jun. 2022 )
=426.446/33.464
=12.74

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Forma Therapeutics Holdings  (NAS:FMTX) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


Forma Therapeutics Holdings Current Ratio Related Terms

Thank you for viewing the detailed overview of Forma Therapeutics Holdings's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Forma Therapeutics Holdings (Forma Therapeutics Holdings) Business Description

Traded in Other Exchanges
N/A
Address
300 North Beacon Street, Suite 501, Watertown, MA, USA, 02472
Forma Therapeutics Holdings Inc is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of novel therapeutics to transform the lives of patients with rare hematologic diseases and cancers. The firm's pipeline products are Etavopivat, FT-7051, FT-8225, and others.
Executives
Agustin Melian officer: EVP, Research & Development C/O ALLOVIR, INC., 139 MAIN STREET, SUITE 500, CAMBRIDGE MA 02142
Brian Andrew Lesser officer: SVP, Commercial Officer C/O FORMA THERAPEUTICS HOLDINGS, INC. 300 NORTH BEACON STREET SUITE 501 WATERTOWN MA 02472
Mary E. Wadlinger officer: See Remarks C/O FORMA THERAPEUTICS HOLDINGS, INC. 500 ARSENAL STREET, SUITE 100 WATERTOWN MA 02472
Jeannette Potts officer: See Remarks C/O FORMA THERAPEUTICS HOLDINGS, INC., 500 ARSENAL STREET, SUITE 100, WATERTOWN MA 02472
Frank D. Lee director, officer: President and CEO C/O FORMA THERAPEUTICS HOLDINGS, INC., 500 ARSENAL STREET, SUITE 100, WATERTOWN MA 02472
David N Cook officer: SVP, Chief Scientific Officer
Patrick F. Kelly officer: SVP, Chief Medical Officer C/O FORMA THERAPEUTICS HOLDINGS, INC. 500 ARSENAL STREET, SUITE 100 WATERTOWN MA 02472
Todd Shegog officer: SVP, Chief Financial Officer 200 SIDNEY STREET, SUITE 320, C/O SYNLOGIC, INC., CAMBRIDGE MA 02139
Arturo Md Molina director 10990 WILSHIRE BLVD, SUITE 1200, LOS ANGELES CA 90024
John E Bishop officer: Chief Technology Officer 675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Vickers Selwyn M Md director 600 NORTH 18TH STREET, BIRMINGHAM AL 35203
Thomas G Wiggans director
Frederick Wayne A.i. director 500 W MAIN ST., LOUISVILLE KY 40202
Peter Kolchinsky director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Healthcare Fund Lp 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116

Forma Therapeutics Holdings (Forma Therapeutics Holdings) Headlines

From GuruFocus

Forma Therapeutics Announces Appointment of New Executive Team Members

By Business Wire Business Wire 06-30-2022